AnaptysBio (NASDAQ:ANAB) Posts Earnings Results, Beats Expectations By $5.57 EPS

AnaptysBio (NASDAQ:ANAB) posted its quarterly earnings results on Monday. The biotechnology company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $5.57, FiscalAI reports. The firm had revenue of $27.49 million for the quarter, compared to analysts’ expectations of $14.06 million.

AnaptysBio Trading Down 0.5%

NASDAQ:ANAB traded down $0.28 during mid-day trading on Monday, hitting $54.92. 493,264 shares of the company’s stock traded hands, compared to its average volume of 694,752. The firm has a 50 day moving average of $56.14 and a two-hundred day moving average of $59.25. The firm has a market capitalization of $1.63 billion, a price-to-earnings ratio of -50.85 and a beta of 0.71. AnaptysBio has a 12 month low of $13.66 and a 12 month high of $72.36.

Analyst Ratings Changes

Several analysts recently commented on ANAB shares. HC Wainwright restated a “buy” rating and issued a $95.00 target price on shares of AnaptysBio in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a research note on Friday, August 7th. Scotiabank downgraded AnaptysBio to a “hold” rating and set a $70.00 price objective for the company. in a research note on Tuesday, August 25th. Wolfe Research reiterated an “outperform” rating and issued a $78.00 price objective on shares of AnaptysBio in a research note on Monday, August 31st. Finally, Zacks Research lowered AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Eleven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $79.85.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases.